Tamoxifen pharmacogenomics

The role of CYP2D6 as a predictor of drug response

Matthew Philip Goetz, A. Kamal, M. M. Ames

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Tamoxifen continues to be a standard endocrine therapy for the prevention and treatment of estrogen receptor (ER)-positive breast cancer. Tamoxifen can be considered a classic "pro-drug," requiring metabolic activation to elicit pharmacological activity. CYP2D6 is the rate-limiting enzyme catalyzing the conversion of tamoxifen into metabolites with significantly greater affinity for the ER and greater ability to inhibit cell proliferation. Both genetic and environmental (drug-induced) factors that alter CYP2D6 enzyme activity directly affect the concentrations of the active tamoxifen metabolites and the outcomes of patients receiving adjuvant tamoxifen. The a priori knowledge of the pharmacogenetic variation known to abrogate CYP2D6 enzyme activity may provide a means by which the hormonal therapy of breast cancer can be individualized.

Original languageEnglish (US)
Pages (from-to)160-166
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume83
Issue number1
DOIs
StatePublished - Jan 9 2008

Fingerprint

Cytochrome P-450 CYP2D6
Pharmacogenetics
Tamoxifen
Pharmaceutical Preparations
Estrogen Receptors
Enzymes
Breast Neoplasms
Prodrugs
Therapeutics
Cell Proliferation
Pharmacology

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tamoxifen pharmacogenomics : The role of CYP2D6 as a predictor of drug response. / Goetz, Matthew Philip; Kamal, A.; Ames, M. M.

In: Clinical Pharmacology and Therapeutics, Vol. 83, No. 1, 09.01.2008, p. 160-166.

Research output: Contribution to journalArticle

@article{0db45423a1724bbd9619280d6f8a8886,
title = "Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response",
abstract = "Tamoxifen continues to be a standard endocrine therapy for the prevention and treatment of estrogen receptor (ER)-positive breast cancer. Tamoxifen can be considered a classic {"}pro-drug,{"} requiring metabolic activation to elicit pharmacological activity. CYP2D6 is the rate-limiting enzyme catalyzing the conversion of tamoxifen into metabolites with significantly greater affinity for the ER and greater ability to inhibit cell proliferation. Both genetic and environmental (drug-induced) factors that alter CYP2D6 enzyme activity directly affect the concentrations of the active tamoxifen metabolites and the outcomes of patients receiving adjuvant tamoxifen. The a priori knowledge of the pharmacogenetic variation known to abrogate CYP2D6 enzyme activity may provide a means by which the hormonal therapy of breast cancer can be individualized.",
author = "Goetz, {Matthew Philip} and A. Kamal and Ames, {M. M.}",
year = "2008",
month = "1",
day = "9",
doi = "10.1038/sj.clpt.6100367",
language = "English (US)",
volume = "83",
pages = "160--166",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Tamoxifen pharmacogenomics

T2 - The role of CYP2D6 as a predictor of drug response

AU - Goetz, Matthew Philip

AU - Kamal, A.

AU - Ames, M. M.

PY - 2008/1/9

Y1 - 2008/1/9

N2 - Tamoxifen continues to be a standard endocrine therapy for the prevention and treatment of estrogen receptor (ER)-positive breast cancer. Tamoxifen can be considered a classic "pro-drug," requiring metabolic activation to elicit pharmacological activity. CYP2D6 is the rate-limiting enzyme catalyzing the conversion of tamoxifen into metabolites with significantly greater affinity for the ER and greater ability to inhibit cell proliferation. Both genetic and environmental (drug-induced) factors that alter CYP2D6 enzyme activity directly affect the concentrations of the active tamoxifen metabolites and the outcomes of patients receiving adjuvant tamoxifen. The a priori knowledge of the pharmacogenetic variation known to abrogate CYP2D6 enzyme activity may provide a means by which the hormonal therapy of breast cancer can be individualized.

AB - Tamoxifen continues to be a standard endocrine therapy for the prevention and treatment of estrogen receptor (ER)-positive breast cancer. Tamoxifen can be considered a classic "pro-drug," requiring metabolic activation to elicit pharmacological activity. CYP2D6 is the rate-limiting enzyme catalyzing the conversion of tamoxifen into metabolites with significantly greater affinity for the ER and greater ability to inhibit cell proliferation. Both genetic and environmental (drug-induced) factors that alter CYP2D6 enzyme activity directly affect the concentrations of the active tamoxifen metabolites and the outcomes of patients receiving adjuvant tamoxifen. The a priori knowledge of the pharmacogenetic variation known to abrogate CYP2D6 enzyme activity may provide a means by which the hormonal therapy of breast cancer can be individualized.

UR - http://www.scopus.com/inward/record.url?scp=37549006389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549006389&partnerID=8YFLogxK

U2 - 10.1038/sj.clpt.6100367

DO - 10.1038/sj.clpt.6100367

M3 - Article

VL - 83

SP - 160

EP - 166

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -